What are the guidelines for treatment of chronic HCV infection in PEG-IFN/ribavirin treatment-experienced genotype 1a patients with compensated cirrhosis?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print
Answer

HCV genotype 1a PEG-IFN/ribavirin treatment-experienced patients with compensated cirrhosis

Recommended regimens 

  • Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks if no baseline NS5A RASs for elbasvir are detected
  • Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks
  • Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) for 12 weeks

Alternative regimens 

  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin for 12 weeks
  • Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) with weight-based ribavirin for 16 weeks in patients who have baseline NS5A RASs for elbasvir

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!